Friday, 23 Aug 2019

You are here

Vitamin D Supplements Fail to Prevent Type 2 Diabetes - DUH!

A NEJM report shows that the use of vitamin D3 supplementation (4000 IU per day) in those without diabetes or vitamin D deficiency failed to significantly lower risk of type 2 diabetes (compared to placebo).

The rational for this report included observational data showing an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes.

They included adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter; and glycated hemoglobin level, 5.7 to 6.4%). The primary outcome was the time to develop new-onset diabetes, with a target number of diabetes events of 508.

A total of 2423 participants were randomized to either vitamin D or placebo. By month 24, the mean serum 25-hydroxyvitamin D level in the vitamin D group was 54.3 ng per milliliter (up from 27.7 ng/ml at baseline), as compared with 28.8 ng per milliliter in the placebo group (baseline = 28.2 ng/ml).

The primary outcome of developing diabetes occurred

  • Vitamin D group: 293 events (9.39 per 100 person-years)
  • Placeboe group: 323 events (10.66  per 100 person-years)
  • Hazard ratio = 0.88 (95% confidence interval, 0.75 to 1.04; P=0.12)
  • No differences in the incidence of adverse events

(Editors note: I am continually amazed at the number of associations between vitamin D levels and poor health; yet there are little or not studies showing that Vitamin D Supplementation cures, fixes or prevents anything.  Certainly Vitamin D is important for bone health and immune function - but that's about where it ends.  I suggest we continue to take vitamin D supplements (since most of are deficient) daily and stop believing that this supplment is the magic bullet for health)


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants

The comparative risk for gastrointestinal bleeding (GIB) with non-vitamin K antagonist oral anticoagulants (NOACs) was compared to vitamin K antagonists or anti-platelet agents in a recent metanalysis, which showed no significant difference in major GIB events between these agents.

Rituximab Superior to Cyclosporine for Membranous Nephropathy

The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. 

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

FDA Public Review of CBD Oil

The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.

In his opening remarks, the FDA acting Commissioner Dr. Ned Sharpless said, "critical questions remain about the safety" of CBD products, especially since the growth of the CBD market has exploded in the past year.